Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach

David Ginn, David Kelsen, Mario Eisenberger, Robert Heelan, Gordon Magill

Research output: Contribution to journalArticlepeer-review

Abstract

Twenty-five previously untreated patients with advanced adenocarcinoma of the upper gastrointestinal tract were treated with a combination of carboplatin and vinblastine. Two partial responses (duration three months and six months) were seen among 22 evaluable patients. Myelosuppression was the most common toxicity and was generally mild. The 8% response rate, (95% confidence interval 2 to 24%) observed in this study indicated that carboplatin-vinblastine has only modest activity in adenocarcinoma of the upper gastrointestinal tract. Although less toxic, this regimen appears to be less effective than previously reported cisplatin-containing regimens in adenocarcinoma of the upper GI tract.

Original languageEnglish (US)
Pages (from-to)321-324
Number of pages4
JournalInvestigational New Drugs
Volume8
Issue number3
DOIs
StatePublished - Aug 1 1990
Externally publishedYes

Keywords

  • carboplatin gastric cancer phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of carboplatin and vinblastine in adenocarcinoma of the stomach'. Together they form a unique fingerprint.

Cite this